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Abstract
Dendritic cells (DC) are potent inducers of natural killer (NK) cells. There are two distinct populations in blood, myeloid
(mDC) and plasmacytoid (pDC) but they can also be generated In vitro from monocytes (mdDC). Although it is established
that blood DC are lost in HIV-1 infection, the full impact of HIV-1 infection on DC-NK cell interactions remains elusive. We
thus investigated the ability of pDC, mDC, and mdDC from viremic and anti-retroviral therapy-treated aviremic HIV-1+
patients to stimulate various NK cell functions. Stimulated pDC and mdDC from HIV-1+ patients showed reduced secretion
of IFN-a and IL-12p70 respectively and their capacity to stimulate expression of CD25 and CD69, and IFN-c secretion in NK
cells was also reduced. pDC activation of NK cell degranulation in response to a tumour cell line was severely reduced in
HIV-1+ patients but the ability of mDC to activate NK cells was not affected by HIV-1 infection, with the exception of HLA-DR
induction. No differences were observed between viremic and aviremic patients indicating that anti-retroviral therapy had
minimal effect on restoration on pDC and mdDC-mediated activation of NK cells. Results from this study provide further
insight into HIV-1 mediated suppression of innate immune functions.
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Introduction
Natural killer (NK) cells are the principal effectors of the innate
system and play a pivotal role in tumour surveillance and anti-viral
immunity [1,2]. In the context of HIV-1 infection, NK cells may
partially control the virus, especially at the early stages of HIV-1
infection before adaptive immunity is initiated [3]. NK cells have
been shown to directly or indirectly kill HIV-1 infected cells as well
as block HIV-1 entry and replication through secretion of a
number of cytokines and chemokines including IFN-c, TNF-a,
and CCR5 binding CC chemokines [4–7].
Dendritic cells (DC) are antigen presenting cells which act as
sentinels for the immune system by engulfing pathogens,
processing and presenting them to CD4 and CD8 T cells. They
express a variety of pattern recognition receptors including toll-like
receptors (TLR) allowing recognition of a wide range of pathogens
(reviewed in [8]). DC are a heterogeneous population of cells
found in blood and most peripheral tissues, particularly at
interfaces with the external environment. In humans, two major
DC subtypes have been described in peripheral blood, myeloid
(mDC) and plasmacytoid DC (pDC), serving different functions.
mDC are thought to be the precursors of tissue DC and efficiently
capture antigen for presentation and stimulation of CD4 and CD8
T cells. They express TLRs 1, 2, 3, 4, 5, 6, and 8 resulting in their
ability to respond to stimulation with bacterial cell wall
components and viral RNA [9,10]. Whilst pDC can also present
antigen to T cells, they uniquely secrete large amounts of IFN-a
that contributes to anti-viral immunity [11,12]. pDC express
TLR-7 and TLR-9 and are therefore responsive to RNA viruses,
and bacterial DNA containing unmethylated CpG sequences
[10,13].
DC are a rare cell type both in the periphery and in lymphoid
organs, constituting about 1% of mononuclear leukocytes, which
makes their study demanding. However, DC can be generated in
large numbers In vitro by culturing peripheral monocytes in the
presence of GM-CSF and IL-4 [14] and such cells have provided
much of our current understanding of human DC biology.
Although, the principal function attributed to DC is their ability
to prime, modulate, and maintain T and B cell responses, evidence
collected over the last decade suggests that DC play an essential
role in shaping NK cell-mediated immunity. Both in vivo [15,16]
and in vitro studies [17–20] have demonstrated that activated DC
can stimulate activation, proliferation, IFN-c production, and
cytolytic activity of NK cells. The interactions between DC and
NK cells are not unidirectional as shown by a number of reports
[17,18]. Activated NK cells can kill immature DC [19,20] thereby
providing a selection mechanism for DC that are competent at
priming T cells. NK cells have also been shown to be capable of
inducing maturation and type I polarisation of DC in the absence
of TLR stimulation, which may be important in the initiation of
adaptive immunity against transformed and tumourigenic cells
(reviewed in [21]).
In the setting of HIV infection, several reports have identified
both numerical and functional defects in the DC and NK cell
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HIV-1 infection on DC-NK bidirectional interplay. Two recent
studies [30,31] have addressed pDC-NK cell interactions during
HIV-1 infection. Reitano et al found reduced amounts of IFN-a
and TNF-a in CpG stimulated PBMC from untreated and
HAART-treated patients, and impaired activation of NK cells, as
indicated by CD69 expression, due to decreased levels of, and
decreased responsiveness to, the pDC produced cytokines [31].
The study by Conry et al found that NK cells from untreated
patients were defective in the pDC mediated IFN-c production
and killing activity, the former being due to both impaired pDC
and NK function whilst the latter was mainly due to NK cell
defects. Killing activity by NK cells was recovered in HAART-
treated patients but IFN-c production remained reduced [30].
Here we have further characterised the extent of pDC impairment
by analysing several NK cell functions including expression of
CD69 and CD25, IFN-c production, and tumour killing potential
in HAART- treated and untreated HIV-1 infected individuals. In
addition, for the first time to our knowledge, we have analysed the
function of mDC and mdDC from HIV-1 infected individuals in
the activation of allogeneic NK cells.
Materials and Methods
Study subjects
The patient cohort consisted of 13 treatment-naı ¨ve and 12
HAART-treated HIV-1 infected individuals. Patients were
selected randomly from those attending an HIV clinic at the
Kobler centre, Chelsea and Westminster Hospital (London,
United Kingdom). Untreated patients were not on anti-retroviral
therapy and had CD4 T cell counts ranging from 41–1000 cells/ml
(median of 255 cells/ml, Table 1) and plasma viral loads ranging
from 202 to greater than 500,000 copies/ml (median of 14337
copies/ml, Table 1). All treated patients had been receiving
HAART for at least 4.4 years. Their CD4 counts at the time of
blood collection ranged from 185 to 1000 cells/ml (median of 500
cells/ml, Table 1) and they all had undetectable viral loads (,50
copies/ml). 12 control samples were obtained from HIV-1
seronegative individuals and single donor buffy coats (the National
Blood Bank, Colindale, London). The latter were used to obtain
large numbers of NK cells. Ethical approval and informed consent
were obtained prior to blood donation.
Cell isolations
60 ml of blood was collected from all participants in EDTA-
coated Vacutainers. Peripheral blood mononuclear cells (PBMC)
were isolated within 4 hours of blood collection by Ficoll-
Histopaque centrifugation (Sigma Aldrich, Poole, UK). PBMC
were resuspended in RPMI (HEPES modification) medium
supplemented with 2% fetal calf serum (FCS), 100 IU penicillin/
streptomycin, and 2 mM L-glutamine (all from Sigma Aldrich,
UK) and stored overnight at 4uC. mDC and pDC were isolated
from PBMC by BDCA1 and BDCA4 positive magnetic bead
isolation according to the manufacturer’s guidelines (Miltenyi
Biotec, Germany). mdDC were generated by culturing positively
isolated CD14
+ monocytes (Miltenyi Biotec, Germany) for 7 days
in the presence of GM-CSF (150 IU/ml, Immunex, USA) and IL-
4 (1000 U/ml, R&D systems, UK). Single donor buffy coats
(obtained from the National Blood Bank, Colindale, London) were
used as a source of allogeneic healthy NK cells. In brief, PBMC
were isolated as outlined above and NK cells were purified by
means of CD56 immunomagnetic bead isolation (Miltenyi biotec,
Germany) followed by depletion of NKT cells using anti-CD3
Dynal beads (Invitrogen, UK). Cells were then stored at 2140uC
in FCS containing 10% dimethyl sulfoxide (DMSO, both from
Sigma Aldrich, UK) for later use. Purity of the isolated cell subsets
(above 90%) was verified by flow cytometry prior to co-culture
experiments.
DC- NK co-cultures
Immature and mature DC subsets were co-cultured with
allogeneic NK cells for 24 hours at a ratio of 1:5. Freshly isolated
pDC were used as immature pDC whereas mature pDC were
generated by stimulation with CpG ODN 2216 (10 mg/ml,
Invivogen, UK). mDC and mdDC were matured with 1 mg/ml
LPS. In all experiments, maturation of DC was performed while
co-cultured with NK cells thus limiting the ex vivo culture to a
total of 24 hours. This was performed in order to minimise cellular
death associated with extended in vitro culture periods, especially
in cells from viremic HIV-1 patients. Co-culture supernatants were
collected and stored at 280uC for cytokine detection by ELISA.
Cells were then harvested and labelled for phenotypic analysis or
co-cultured with K562 cells for killing/degranulation assays.
Flow cytometry
Flow cytometric analysis was performed using the following
antibodies: anti CD3, CD25, CD69, CD56, CD107a, Lineage,
CD11c, CD123, and HLA-DR antibodies (all from Pharmingen
or BD biosciences, UK). Cells from co-culture experiments were
washed and resuspended in PBS containing 2% FCS, 2 mM
EDTA, and 0.05% NaN3 (FACS buffer, all reagents from Sigma
Aldrich, UK). Cells were stained on ice with the appropriate
antibodies for 30 min, washed with FACS buffer, then fixed with
4% paraformaldehyde in PBS (both from Sigma Aldrich, UK). To
verify cell purity and to initially identify pDC and mDC, cells were
labelled with anti-Lineage, CD123, CD11c, and HLA-DR
antibodies. Purity of isolated NK cells was confirmed using
CD16, CD56, and CD3 antibodies (all from Pharmingen or BD
biosciences, UK). All isolated cells used in this study had a purity
of over 90%. Appropriate isotype controls were used to assess non
specific binding of the antibodies used. Cells were acquired using a
fluorescent-activated cell sorter (FACS-calibur) or an LSR-II (both
from BD). Data analysis was performed using Cell Quest Pro
software package or FACS-DIVA 5.0.1 (both from BD).
Degranulation assay
The ability of NK cells to degranulate in response to co-culture
with K562 cells was assessed as previously described [32]. In brief,
NK cells that had been cultured alone or with DC subsets were
further incubated for 4 hours with K562 cells at a 5:1 ratio in the
presence of Brefeldin-A (BFA, 10 mg/ml, Sigma Aldrich), 6 mg/ml
monensin (Sigma Aldrich), and anti-human CD107a antibody or
its matching isotype control (Pharmingen, BD). Cells were
harvested after 4 hours of co-culture and washed in FACS buffer.
Cells were then labelled with anti CD3 and CD56 antibodies for
30 mins on ice washed and then fixed with 4% PFA in PBS.
Specific staining for CD107a on CD56
+ CD3
2 cells (NK cells) was
assessed by flow cytometry as described above.
Cytokine detection
IFN-a and IFN-c levels in immature and mature DC-NK co-
culture supernatants were measured by commercially available
ELISA kits. Supernatants were centrifuged and IFN-a and IFN-c
levels measured with human interferon-a multi-subtype ELISA
(PBL Interferon Source, USA) and IFN-c ELISA (R&D Systems,
UK) kits. All ELISAs were performed in accordance with the
manufacturers’ guidelines. ELISA Plates were read on an Anthos
DC Induced NK Cell Activation in HIV-1
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using GraphPad prism 5 (GraphPad Software, San Diego, CA).
Statistical analysis
Data are expressed as median and IQR or mean 6 standard
deviation after background subtraction. We used non parametric
tests throughout as normality of data distribution could not be
tested. We employed the Mann-Whitney U test to determine
significance between two un-paired groups and the wilcoxon Rank
test to compare paired samples. The Spearman R test was used to
determine correlations between two variables. All statistical tests
were two-sided and were performed using GraphPad Prism 5
(GraphPad Software, San Diego, CA). p,0.05 was considered
statistically significant.
Results
Blood DC are depleted in HIV-1 patients
We first investigated the effect of HIV-1 infection on circulating
blood DC counts. This was achieved by first indentifying the
percentages of pDC and mDC within PBMC by flow cytometry on
the basis of lack of expression of lineage markers (CD3, CD14,
CD16, CD19, CD20, and CD56), expression of HLA-DR, and
expression of either CD11c for mDC or CD123 for pDC
(Figure 1A). DC counts were then calculated on the basis of their
percentages, the total live count of PBMC, and volume of blood
collected. As shown in Figure 1B, we confirmed previous
observations [26–28] that total blood DC numbers are depleted
in HIV-1 infected individuals with a median of 3.5 cells/ml (range
3.2 to 12.6 cells/ml, p=0.03) in therapy-naı ¨ve patients, and 2.3
cells/ml (range 1.1 to 8.1 cells/ml, p=0.002) in HAART-treated
patients as compared to a median of 14.1 cells/ml (range 8.6 to 17.3
cells/ml) in healthy controls. Both pDC and mDC counts were
reduced in untreated HIV patients with a median of 1.2 cells/ml
(range 0.8 to 3.8 cells/ml, p=0.01), and 1.6 cells/ml (range 0.9 to 2.1
cells/ml, p=0.004) in pDC and mDC respectively compared to
pDC (median of 4.1, range 2.6 to 5 cells/ml) and mDC numbers
(medianof4.1cells/ml,range 3.4to 10.7cells/ml)inhealthycontrols
(Figure 1C and D). There was no recovery of pDC and mDC
numbers in patients receiving HAART therapy with a median of
1.3 cells/ml (range 0.2 to 4.8 cells/ml, p=0.01) and 0.7 cells/ml
(range 0.1 to 2.6 cells/ml, p=0.002) respectively (Figure 1C and D).
Table 1. Clinical characteristics of HIV-1 patient cohorts.
Patient ID Treatment history Years on therapy Age (years) CD4 count (cell/ml)
Plasma VL
(copies/ml)
Control group
(n=12) Healthy controls n.a.
Median (30)
range (23–60) n.t. n.a.
N01 Naı ¨ve n.a. 46 214 500000
N02 Naı ¨ve n.a. 36 69 226208
N03 Naı ¨ve n.a. 38 198 1163
N04 Naı ¨ve n.a. 33 362 202
N05 Naı ¨ve n.a. 41 350 7000
N06 Naı ¨ve n.a. 42 460 324414
N07 Naı ¨ve n.a. 40 1000 10000
N08 Naı ¨ve n.a. 36 41 100389
N09 Naı ¨ve n.a. 60 957 20497
N10 Naı ¨ve n.a. 33 255 68342
N11 Naı ¨ve n.a. 30 215 14337
N12 Naı ¨ve n.a. 37 451 1480
N13 Naı ¨ve n.a. 47 191 14069
Median (range) - - 38 (30–60) 255 (41–1000) 14337 (202–500000)
H01 HAART 5.5 41 500 ,50
H02 HAART 4.4 54 390 ,50
H03 HAART 5.4 50 1000 ,50
H04 HAART 5.6 45 500 ,50
H05 HAART 5.9 43 405 ,50
H06 HAART 8.3 43 548 ,50
H07 HAART 8.7 41 961 ,50
H08 HAART 5.8 53 302 ,50
H09 HAART 3.9 44 185 ,50
H10 HAART 11.6 43 505 ,50
H11 HAART 11.6 47 705 ,50
H12 HAART 4.0 59 414 ,50
Median (range) - 5.7 (3.9–11.6) 44.5 (41–59) 500 (185–1000) ,50
n.a: not applicable, m: male, f: female, n.t. not tested.
doi:10.1371/journal.pone.0017525.t001
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impaired NK cell activation capacity
We next sought to investigate the functional competency of
pDC to activate NK cells. Since several studies have indicated
defects in the NK compartment during HIV-1 infection [22–25],
we utilised an allogeneic system whereby NK cells were isolated
from healthy donors (buffy coats) and co-cultured with pDC that
were purified from the different patient groups. This was feasible
due to the MHC-non-restricted properties of NK cell activation.
To monitor NK activation we measured the expression levels of a
number of surface receptors by flow cytometry. As shown in
Figure 2, co-culture of NK cells with immature pDC that were
isolated from healthycontrols orHIV-1patients resultedinminimal
activation of NK cells as assessed by lack of expression of CD69,
HLA-DR, and CD25. Additionally, there was no or minimal
degranulation by NK cells following co-culture with K562 cells, an
NK sensitive tumorogenic cell line, or on culture with immature
pDC. However, addition of CpG DNA (a TLR-9 ligand) to pDC-
NK cell co-cultures from healthy donors resulted in substantial
upregulation of CD69 and CD25 by NK cells (Figure 2A and 2C).
Thiswasstatisticallysignificant with p valuesequal to 0.001 for both
receptors (Wilcoxon paired test) in comparison to immature pDC-
Figure 1. pDC and mDC counts are reduced in HIV-1 infection. A) The gating strategy used to identify blood pDC and mDC within PBMC. B)
C) and D) show total DC, pDC, and mDC counts per ul of blood respectively. DC counts were calculated based on their percentages within PBMC,
total PBMC live counts (Trypan blue exclusion method), and the volume of blood collected. * and ** indicate P values less than 0.05 and 0.01
respectively (Mann Whitney U test).
doi:10.1371/journal.pone.0017525.g001
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following a 4 hour co-culture with K562 cells was increased above
background levels by at least 2–3 fold when NK cells were co-
cultured with CpG DNA-matured pDC that were purified from
healthy donors (p=0.001, Wilcoxon test, Figure 2D). There was
marked impairment in the ability of CpG DNA treated pDC from
HIV-1 infected individuals, regardless of their therapy status, to
activate NK cells with respect to expression of CD69, CD25, and
CD107a compared with healthy controls (Figure 2).
HLA-DR expression by allogeneic NK cells was not up-regulated
by co-culture with mature pDC from healthy donors. Interestingly,
HLA-DR expression on NK cells was lower when they were co-
cultured with stimulated or unstimulated pDC from HIV-1 infected
individualsregardlessoftheirtherapystatus(Figure2B).Ofnote,we
evaluated the effects of TLR ligands used in this study (CpG DNA
and LPS) on NK cell in the absence of DC for control purposes.
Both TLR ligands had minimal to no effect with regards to CD69,
HLA-DR, CD25, and CD107a expression by NK cells (Figure S1).
mdDC but not mDC have impaired NK stimulatory
functions in HIV-1 patients
Since we observed a reduced ability of pDC from HIV-1
infected subjects to stimulate NK cells, we evaluated the functional
competency of other DC subsets. We repeated the co-culture
experiments using blood mDC and In vitro generated DC derived
from monocytes (mdDC) using blood from 6 healthy controls and
untreated, N01–N07, or HAART treated H01–H06 HIV-1
infected patients (Table 1). Similar to immature pDC, unstimu-
lated mDC and mdDC isolated or generated from healthy controls
or HIV-infected individuals lacked the ability to activate allogeneic
NK cells (data not shown). When mDC and mdDC from healthy
controls were stimulated with LPS, a TLR-4 ligand, then co-
cultured with allogeneic NK cells, we observed an increase in
CD69 and CD25 expression by NK cells (Figure 3A and C). Up-
regulation of these two receptors was more pronounced when
mature mdDC were used in comparison to mDC (Figure 3 A and
C). Unlike pDC, both LPS-matured mDC and mdDC from
healthy individuals were capable of stimulating moderate levels of
HLA-DR expression by NK cells (Figure 3 B).
LPS-matured mDC that were isolated from HIV-1 infected
patients retained the ability to activate NK cells with regards to
CD69, CD25, and CD107a expression (Figure 3 A and C).
However, the ability of mDC from therapy naı ¨ve patients to
stimulate HLA-DR up-regulation by NK cells was severely
reduced (mean of 1.361.5%, p=0.001) in comparison to healthy
donors (Figure 3B). This function was moderately restored in
HAART-treated HIV-1
+ individuals (mean of 6.165.0%), al-
though it did not reach statistical significance in comparison to
viraemic patients (p=0.05, Figure 3 B).
On the other hand, mdDC that were generated from HIV
patients showed a diminished ability to activate NK cells with
regard to CD69 and CD25 expression. This reduction was
statistically significant in comparison to mdDC from healthy
individuals(Figure3AandC).Conversely,therewerenostatistically
significant differences between the different cohorts with regards to
the ability of mdDC to induce NK-cell expression of HLA-DR
(Figure 3B) anddegranulation inresponsetoK562cells(Figure 3D).
Reduced secretion of interferon c by NK cells co-cultured
with mature pDC or mature mdDC from HIV-1-infected
patients
Although the primary function attributed to NK cells is direct
killing of tumourogenic and virally-infected cells, a subset of
activated NK cells can also secrete large amounts of IFN-c, a Th1
promoting cytokine with anti-viral properties. We measured the
levels of this cytokine in DC-NK cultures from the two patient
groups and controls. NK cells that were cultured alone or with
immature DC had undetectable IFN-c levels (below the detection
limit of 15 pg/ml, data not shown). In contrast, cultures
containing NK cells and CpG-matured pDC or LPS-stimulated
mdDC from healthy controls produced significant amounts of
IFN-c (means of 7716243 and 12016245 pg/ml respectively,
Figure 4A). By contrast, mature pDC and mdDC from HIV-1
patients were notably impaired at inducing IFN-c secretion by NK
cells (Figure 4A). There were slightly higher IFN-c levels in
cultures containing mature pDC and mdDC from HAART-
treated patients in comparison to untreated individuals (Figure 4A).
Nonetheless, these levels remained significantly lower in compar-
ison to healthy controls, indicating that ART therapy does not
restore the functional competency of pDC and mdDC to induce
IFN-c production by allogeneic NK cells.
We and others [18,33,34] have demonstrated that pDC
mediated activation of NK cells is partly mediated through
secretion of IFN-a, whereas mdDC stimulate NK cells through an
IL-12 dependent mechanism [35]. Therefore, we measured the
levels of IFN-a and IL-12p70 in cell culture supernatants
containing mature pDC and mdDC respectively. As can be seen
in Figure 4B, large amounts of IFN-a were detected in cultures
containing CpG DNA-matured pDC from healthy controls. In
contrast, pDC from therapy naı ¨ve patients secreted significantly
lower levels of IFN-a in response to CpG DNA (Figure 4B). pDC
from therapy-treated HIV-1 patients produced slightly more IFN-
a than that produced by pDC from untreated patients but this was
still 2–3 fold lower than pDC from healthy individuals (Figure 4B).
Similarly, IL-12p70 secretion by LPS-matured mdDC was found
to be severely diminished in HIV-1 patients (Figure 4C) regardless
of their therapy status.
Contrary to pDC and mdDC, LPS-matured mDC from the
different groups failed to induce NK-mediated IFN-c secretion.
This may reflect their limited ability to secrete IL-12 upon single
TLR stimulation as previously described by Napolitani et al [36].
Discussion
It is well established that HIV infection reduces both DC and
NK cell numbers and function [22–29]. The objective of the
current study was to investigate the ability of DC subsets from
HIV-1 infected patients to stimulate various NK cell functions.
pDC from HIV-1 seropositive individuals exhibited a defective
capacity to induce NK-associated activation markers tested
including CD69, an early activation marker expressed by NK
cells committed to cytolytic activity [37,38]; HLA-DR expressed
by a subset of activated NK cells [39]; CD25 - associated with
increased NK proliferative capacity [38]; and CD107a - a marker
of lysosomal granule exocytosis that correlates with NK-mediated
cytolytic activity [32]. Although mDC are generally not as potent
as mdDC in activation of NK, their NK-stimulatory competency
was unaltered during HIV-1 infection, except for HLA-DR up-
regulation, whereas mdDC from HIV-1 infected individuals
displayed defects in their ability to stimulate CD25 and CD69
up-regulation by NK cells. Notably, pDC and mdDC defects did
not correlate with the patients’ CD4 T cell counts or plasma viral
loads (data not shown), which may indicate that these impairments
are not directly associated with disease progression.
Defects, which were not reversed by HAART treatment, may
be attributed to DC and not NK cells as we have utilised an
allogeneic In vitro system in which DC from HIV-1 infected
DC Induced NK Cell Activation in HIV-1
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seronegative individuals. Of note, the ability of NK cells from
healthy individuals to respond to allogeneic DC was comparable
to autologous DC, at least in terms of CD69 expression (data not
shown). However we cannot eliminate the possibility that NK cells
were able to kill allogeneic DC through recognition of mismatched
HLA-C molecules as suggested by a number of In vitro [40] and in
vivo studies [41]. Nonetheless, we observed minimal NK activation
in the absence of stimulatory ligands following co-culture with
allogeneic immature DC as assessed by expression of CD69,
CD25, HLA-DR, and secretion of IFN-c (Figure 2 and data not
shown). This experimental setup has been recently used in a
similar study to ours [30].
The effect of HIV-1 infection on circulating DC numbers has
been addressed in a number of studies. Both mDC and pDC
numbers are significantly lower in chronically infected patients
[26,27]. However, the effect of antiretroviral therapy on
restoration of DC numbers in the periphery of HIV-1 infected
individuals remains inconclusive. Chehimi et al showed that
HAART treatment had no beneficial effect on pDC and mDC
percentages and numbers [42], whereas Baron et al and Kamga et
al found that HAART treatment during the acute phase of HIV-1
infection restored blood DC counts [28,43], and Finke et al
demonstrated partial reconstitution of DC numbers in chronically
infected patients receiving therapy [44]. In the present study ART
therapy was found to be ineffective at restoring DC numbers.
Notably, DC reduction in the periphery of HIV-1 patients may
reflect their migration to secondary lymphoid tissue as shown in
primary infection [45].
In our HIV-1 cohorts we observed functional defects in pDC in
their ability to stimulate NK cells. In a recent report by Conry et al
[30], the authors demonstrated that pDC mediated activation of
NK cell secretion of IFN-c and granzyme B production was
impaired during HIV-1 infection. Similarly, Reitano and col-
leagues showed that CpG-DNA stimulation of PBMC from
viraemic and aviraemic HIV-1 patients resulted in lower levels of
CD69 expression by NK cells compared to healthy controls [31].
In both studies, impaired pDC-NK interactions in HIV-1 infected
individuals were attributed to defects in the pDC and NK cell
compartments, with pDC secreting lower amounts of IFN-a and
TNF-a upon CpG DNA stimulation [31] whilst NK cells were
refractory to type I interferon [30] due to expression of high levels
of interferon-inducible genes (IFIGs) [31].
Although pDC from healthy individuals secrete abundant
amounts of IFN-a in response to stimulation with TLR-7 and 9
ligands [10,13,46,47], there is a consensus in the literature
regarding a diminished type I IFN secretory ability of pDC from
HIV-1 infected patients during primary [43,48] and chronic
infection [49]. However, the effect of anti-retroviral treatment on
pDC functions remains controversial. On the one hand, it has
been suggested that initiation of HAART during acute [43,48,50]
and chronic [51] HIV-1 infection restores pDC numbers and their
ability to secrete IFN-a production upon maturation. On the other
hand, Reitano and colleagues showed no reconstitution in pDC-
mediated production of IFN-a in HIV-1 patients receiving anti-
retroviral therapy [31]. Findings of the current study suggest that
HAART treatment did not restore circulating pDC numbers nor
did it reverse the refractory nature of pDC to CpG DNA
stimulation. However, HAART treated patients who were
recruited in this study had received therapy for a median of 5.7
years and it remains plausible that recovery of pDC numbers and
function in terms of type I interferon production in these
individuals may require a longer period of viral suppressive
therapy [52]. Additionally, treated patients recruited in this study
had low nadir CD4 counts (median of 163.5, range 0–784 cells/ml)
prior to HAART initiation, which may have affected full
reconstitution of pDC functions post treatment.
Using unfractionated PBMC, Yonkers et al showed that
accessory cell dependent NK cell activation was impaired in
HIV-1 patients. This impairment was due to defective mDC-NK
interaction and likely a result of the numerical deficiency of mDC
associated with HIV-1 infection rather than a defective ability of
mDC to stimulate NK cells on a per cell basis [53]. This is in
agreement with the finding of the current study where mDC
function appears to be intact in HIV-1 infected individuals.
However, in the study by Yonkers et al, the authors found that
NK-mediated secretion of IFN-c was dependent on mature mDC
and partly dependent on IL-12. Additionally, an earlier report by
Geroza et al indicated that mDC from healthy individuals were
able to activate NK cells through an IL-12-dependent mechanism
[18]. Although these observations seem to contradict the findings
of this report where we observed no IL-12p70 production by LPS-
matured mDC, a possible explanation for this discrepancy is
differences in the stimuli used to mature mDC. Both Yonkers et al
[53] and Geroza et al [18] utilised synthetic Poly-IC which signals
through TLR-3 whereas we used LPS which activates mDC via
TLR-4. In our study, mature mDC failed to induce IFN-c
secretion by NK cells possibly due to their inability to secrete IL-
12p70 in response to LPS, whereas Yonkers et al detected IL-12 in
their cell culture supernatants, albeit the levels were extremely low
(less than 25 pg/ml). Our observation that mDC did not secrete
IL-12 in response to TLR-4 stimulation is consistent with a
previous report [36] indicating that a combination of TLR
agonists are required for synergistic activation of IL-12 p70
production by human blood mDC.
Little is known about the effect of HIV-1 infection on
monocyte-derived DC (mdDC) with respect to their ability to
activate NK cells. Early studies conducted in seronegative controls
suggest that unlike pDC-mediated activation of NK cells which is
dependent on Type I interferon and cellular contact [18,33],
mdDC activate NK cell functions primarily through secretion of
IL-12p70 [17,19]. Thus, it is reasonable to assume that the
diminished ability of mdDC from HIV-1 patients to stimulate NK
cells may be completely or at least partially due to their impaired
IL-12 secretory potential. Indeed, we observed a significant
positive correlation between the levels of IL-12p70 in mdDC-
NK co-culture supernatants and IFN-c secretion by NK cells in all
cohorts (data not shown). Other studies have addressed the
capacity of mdDC from HIV-1 patients to secrete the bioactive
form of IL-12. For instance, Sacchi and co-workers demonstrated
that monocytes from both therapy-naive and treated HIV-1
patients differentiate into CD1a
2 dendritic cells with a defective
Figure 2. CpG-matured pDC are impaired at activating NK cells. pDC isolated from healthy controls or HIV-1 patients were co-cultured with
heterologous NK cells for 24 hours in the presence or absence of CpG DNA (N=12 for healthy controls (open box plots) and HAART treated patients
(striped box plots) and N=13 for therapy naı ¨ve patients(shaded box plots). A), B), and C) show the percentages of CD56
+ CD3
2 NK cells expressing
CD69, HLA-DR, and CD25 respectively. D) NK cells that were co-cultured with pDC were further co-cultured with K562 cells for 4 hours. Box plots
represent the percentages of CD56
+ CD3
2 NK cells expressing CD107a. Data was corrected for background expression of the different makers by NK
cells that were cultured alone or with K562 cells for the same period of time. *, **, and *** indicate P values less than 0.05 and 0.01 and 0.001
respectively using the Mann Whitney U test (straight lines) or the Wilcoxon paired test (dotted lines).
doi:10.1371/journal.pone.0017525.g002
DC Induced NK Cell Activation in HIV-1
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17525DC Induced NK Cell Activation in HIV-1
PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e17525capacity to secrete IL-12p70 in response to In vitro stimulation with
LPS [54]. We have recently assessed the functional competency of
mdDC from HIV-1 infected individuals to stimulate T cell
proliferation and demonstrated that although mdDC express
normal levels of co-stimulatory molecules upon LPS maturation,
they produced significantly lower amounts of IL-12p70 [55].
Similarly, Mavillio et al showed a significant reduction in the
ability of mdDC from viraemic individuals to secrete IL-12p70
with a trend towards recovery on therapy [56]. This was coupled
with a reduction in the ability of mdDC from viremic patients to
induce IFN-c secretion by NK cells [56]. The aforementioned
reports are consistent with the findings presented in Figure 4.
Interestingly, in the study by Mavillio et al [56], mdDC from
viremic patients were also impaired at inducing proliferation of
both autologous and allogeneic NK cells. This is consistent with
our findings regarding a diminished expression of CD25, a marker
associated with proliferation (Figure 3). However, we observed a
partial increase in CD25 expression by NK cells that were co-
cultured with mdDC from aviremic treated patients, though this
remained signficantly less than that observed with mdDC from
healthy donors. The effect of HAART on mdDC function in this
respect, as well as IFN-c secretion, in our cohort is inconsistent
Figure 3. LPS-matured mdDC but not mDC are impaired at activating NK cells. mDC and mdDC from healthy controls (open box plots,
n=6), therapy naı ¨ve (filled box plots, n=7), and HAART treated HIV-1 patients (striped box plots, n=6) were co-cultured with allogeneic NK cells from
healthy donors for 24 hours. A), B) and C) show the percentages of CD56
+ CD3
2 NK cells expressing CD69, HLA-DR, and CD25 respectively. D) NK cells
were further co-cultured with K562 cells for 4 hours in the presence of CD107a antibody. Box plots represent the percentages of CD56
+ CD3
2 NK cells
expressing CD107a. The levels of NK activation using CpG DNA matured pDC from the different cohorts are also given for comparative purposes. All
data was corrected for background expression of the different makers by NK cells that were cultured alone or with K562 cells for the same period of
time. * and ** indicate P values less than 0.05 and 0.01 respectively (Mann Whitney U test).
doi:10.1371/journal.pone.0017525.g003
Figure 4. pDC and mdDC-mediated IFN-c secretion by NK cells is impaired in HIV-1 infection. pDC, mDC, and mdDC from healthy
controls (open bars), therapy naı ¨ve (filled bars), and HAART treated HIV-1 patients (striped bars) were co-cultures with allogeneic NK cells for
24 hours. The levels of IFN-c (A), IFN-a (B), and IL-12p70 (C) were measured in cell-culture supernatants by ELISA. * and ** indicate P values less than
0.05 and 0.01 respectively (Mann Whitney U test).
doi:10.1371/journal.pone.0017525.g004
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recovery of function. This may reflect differences in the type of
treatment, length of therapy, or the patients’ nadir CD4 counts.
As previously mentioned, DC-NK interactions are not unidi-
rectional as it is known that activated NK cells can either lyse
immature DC or induce their maturation depending on NK-DC
ratios [20]. It is thought that through these two mechanisms, NK
cells can either provide a selection mechanism for DC that are
competent at priming T cells or provide a negative regulatory
mechanism of on-going inflammatory responses, whilst NK-
mediated induction of DC maturation in the absence of danger
signals may be important in the initiation of adaptive immune
responses, particularly in anti-tumour immunity. Although the
current report has not directly addressed the effects of NK cells on
DC maturation, it is likely that the decreased levels of IFN-c
secretion by NK cells seen in HIV-1 patients (Figure 4) may result
in lower levels of DC maturation as suggested by Vitale et al [57].
However, further experiments would be required to fully address
these points. With regards to NK-mediated lysis of immature DC,
two early studies [56,58] have demonstrated an impaired ability of
NK cells from HIV-1 infected individuals to kill autologous
immature mdDC. However, HAART therapy was shown to
restore this function in one study [56] whilst Tasca et al found that
this function was conserved in early infection but lost in
chronically infected individuals regardless of their therapy status
[58]. There is no data thus far as to whether NK-mediated killing
of naturally occurring DC (pDC and mDC) is affected during
HIV-1 infection and how this may impact on HIV-1 spreading
and pathogenesis, further experiments are needed to elucidate this
point. In addition, future studies should dissect the precise
mechanisms by which HIV-1 affects this innate NK-DC network.
In conclusion, findings presented in this study suggest that HIV-
1 infection selectively impairs pDC and mdDC-mediated NK
activation. Since NK cells play a pivotal role in anti-HIV-1
immune responses, our results may have implication for future
design of vaccines and immune-based therapies. Additionally, the
observation that HAART had little effect on reconstitution of
these innate functions further implies that alternative therapeutic
strategies are required for an enhanced immune recovery.
Supporting Information
Figure S1 Effect of LPS and CpG DNA on NK cell
activation. Purified NK cells were cultured for 24 hours either
alone (negative control), or in the presence of CpG DNA, LPS, or
phorbol 12-myristate 13-acetate (PMA) and ionomycin (positive
control). Cells were harvested and stained for CD69 (A), HLA-DR
(B), and CD25 (C). NK cells were also co-incubated with K562
cells for 4 hours and CD107a is shown in (D). Filled Histograms
and dotplots represent expression levels by CD56+ CD3- cells
from a representative sample. Dotted lines and quadrants indicate
nonspecific staining using the appropriate isotype controls. Scatter
plots (right) represent cumulative data from all samples and
batches of NK cells used in this study.
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